Repligen (NASDAQ:RGEN) Stock Price Up 10.1% – Should You Buy?

Posted by on Jun 24th, 2026

Repligen Corporation (NASDAQ:RGEN – Get Free Report)’s share price rose 10.1% during mid-day trading on Wednesday . The company traded as high as $139.50 and last traded at $139.1240. 445,146 shares were traded during trading, a decline of 53% from the average daily volume of 956,611 shares. The stock had previously closed at $126.37.

Analysts Set New Price Targets

RGEN has been the subject of a number of recent analyst reports. Roth Mkm initiated coverage on Repligen in a research report on Friday, April 17th. They issued a “buy” rating and a $160.00 price target for the company. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 7th. Barclays raised their target price on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Finally, Canaccord Genuity Group cut their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $164.64.

Get Our Latest Analysis on Repligen

Repligen Stock Up 10.2%

The stock has a market capitalization of $7.86 billion, a price-to-earnings ratio of 154.66, a price-to-earnings-growth ratio of 2.44 and a beta of 1.09. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average of $121.94 and a two-hundred day moving average of $135.79.

Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.25 million during the quarter, compared to analyst estimates of $192.05 million. During the same period last year, the company posted $0.39 EPS. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current year.

Institutional Trading of Repligen

Several institutional investors have recently made changes to their positions in RGEN. Measured Wealth Private Client Group LLC purchased a new position in Repligen during the third quarter valued at approximately $29,000. Bayforest Capital Ltd purchased a new stake in Repligen in the 4th quarter worth approximately $32,000. Rachor Investment Advisory Services LLC acquired a new stake in shares of Repligen during the 4th quarter valued at $33,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the 4th quarter valued at $36,000. Finally, Farther Finance Advisors LLC grew its holdings in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

(Get Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Read More

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.